| Name | Title | Contact Details |
|---|
Coastal Medical, Inc. is Rhode Islands largest, physician owned and physician governed Primary Care practice, serving patients in RI and southeastern Massachusetts.
IM Cannabis (IMC) is one of the world`s pioneering medical-grade cannabis companies, with operations in Israel, across Europe, and Canada. Over the past decade, IMC has established its premium medical cannabis brand, comprising a full spectrum of products known for their quality, consistency, and purity, such as ROMA, TEL AVIV and LONDON. In Europe, IMC has established a fully operational, vertically integrated medical cannabis business, spearheaded by its EU-GMP certified distribution arm in Germany and augmented by strategic alliances with certified pan-EUGMP certified suppliers. To this end, IMC has formed strong strategic alliances within the international medical cannabis industry, aiming for a dominant position in satisfying the global demand for high-quality medical cannabis products, which both physicians and patients can rely upon. IMC further intends to leverage its expertise in Israel in order to bolster its research and development initiative while collaborating with world-renowned scientists on cutting-edge technology for the benefit of patients around the world
Meyer Pharmaceuticals (Main) is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Athenex is a global specialty oncology pharmaceutical company focused on the development and commercialization of next generation therapies for cancer diseases and supportive therapies. The company is dedicated to delivering innovative drugs that can have a life-changing impact on cancer patients. Our business includes medical technology innovation centers and a unique manufacturing supply chain across both China and North America. Through the connected innovation and manufacturing supply chain presence, we can identify, develop and deliver proprietary medical technology across continents and multiple regulatory environments.
Ophthotech is a biopharmaceutical company specializing in the development of novel therapeutics to treat back of the eye diseases, with a focus on developing innovative therapies for age-related macular degeneration (AMD). Ophthotech`s most advanced product candidate, Fovista® anti-PDGF therapy, is in Phase 3 clinical trials for use in combination with anti-VEGF therapy that represents the current standard of care for the treatment of wet AMD. Ophthotech`s second product candidate, Zimura®, an inhibitor of complement factor C5, is being developed for the treatment of geographic atrophy, a form of dry AMD.